2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on …

PA Heidenreich, B Bozkurt, D Aguilar, LA Allen… - Journal of the American …, 2022 - jacc.org
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors

AJ Scheen - Circulation research, 2018 - Am Heart Assoc
Cardiovascular disease (CVD) is a major challenge in the management of type 2 diabetes
mellitus. Glucose-lowering agents that reduce the risk of major cardiovascular events would …

Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities

I Tuleta, NG Frangogiannis - Advanced drug delivery reviews, 2021 - Elsevier
In patients with diabetes, myocardial fibrosis may contribute to the pathogenesis of heart
failure and arrhythmogenesis, increasing ventricular stiffness and delaying conduction …

Diabetes mellitus, blood glucose and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies

D Aune, T Feng, S Schlesinger, I Janszky… - Journal of Diabetes and …, 2018 - Elsevier
Background Diabetes and elevated blood glucose have been associated with increased risk
of atrial fibrillation in a number of epidemiological studies, however, the findings have not …

The safety of gliptins: updated data in 2018

AJ Scheen - Expert opinion on drug safety, 2018 - Taylor & Francis
ABSTRACT Introduction: Dipeptidyl peptidase-4 inhibitors (DPP-4is) are generally
considered as glucose-lowering agents with a safe profile in type 2 diabetes. Areas covered …

Autophagy as an emerging target in cardiorenal metabolic disease: from pathophysiology to management

Y Zhang, AT Whaley-Connell, JR Sowers… - Pharmacology & …, 2018 - Elsevier
Although advances in medical technology and health care have improved the early
diagnosis and management for cardiorenal metabolic disorders, the prevalence of obesity …

2022 ACC/AHA/HFSA guideline for the management of heart failure

PA Heidenreich, B Bozkurt, D Aguilar, LA Allen… - Journal of Cardiac …, 2022 - Elsevier
ABSTRACT Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure

SP Marso, FMM Baeres, SC Bain, B Goldman… - Journal of the American …, 2020 - jacc.org
Background More data regarding effects of glucagon-like peptide-1 receptor agonists in
patients with type 2 diabetes (T2D) and heart failure (HF) are required. Objectives The …

[HTML][HTML] Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes

V Garg, S Verma, K Connelly - Progress in Cardiovascular Diseases, 2019 - Elsevier
The treatment landscape for patients with established or at high risk for cardiovascular
disease and type 2 diabetes mellitus has entirely changed over the past decade, with the …

Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose‐lowering medications

DSH Bell, E Goncalves - Diabetes, Obesity and Metabolism, 2019 - Wiley Online Library
In people with type 2 diabetes the frequency of heart failure (HF) is increased and mortality
from HF is higher than with non‐diabetic HF. The increased frequency of HF is attributable to …